Scientists want to eradicate “Black Death” in Africa using Covid-19 vaccine technology – Yahoo Finance

Scientists at the University of Oxford who were behind the AstraZeneca Covid-19 vaccine have launched a phase 1 trial to test a new vaccine against plague. Centuries after causing one of the worst pandemics in history, the infectious disease (sometimes referred to as “Black Death” or pestilence) continues to afflict parts of Africa, which today accounts for 90% of all reported cases.
Though plague can be successfully treated with antibiotics, there is no vaccine for the disease, and it is still endemic in several countries. Worldwide, more than 3,000 people experienced the disease, and close to 600 people died from it between 2010 and 2015, according to the World Health Organization.
California passed a bill that could dramatically increase its housing stock
The African countries most affected are the Democratic Republic of Congo (DR Congo) and Madagascar, followed by Mozambique, Uganda, and Tanzania.
The vaccine under development is based on the viral vector approach used in the successful AstraZeneca Covid-19 vaccine. It contains a harmless common-cold virus from chimpanzees that has been genetically engineered to transport genes into body cells. They then deliver instructions that trigger an immune response in the body against the disease.
The US may have a new top secret space weapon. What is it?
Plague is caused by the bacterium Yersinia pestis. The disease can take different clinical forms, including bubonic, septicemic, and pneumonic.
The bubonic plague (the most common) and the septicaemic plague are transmitted by infected fleas frequently carried by rats. The pneumonic form, the most infectious, can spread from person to person through airborne droplets from coughing and breathing.
While the bubonic form has a case-fatality of 30-60% if not treated, the septicemic and pneumonic forms has a case-fatality ratio of 30-100% if left untreated. From the 14th century on, the disease spread through Europe, north Africa, and Eurasia, eventually killing millions of people.
The phase-one trial is funded by Innovate UK, which is part of the UK Research and Innovation, a branch of the government. It will involve at least 40 participants from age 18 to 55, with the aim to determine how effective it is in protecting against the disease, and assess any side effects.
The biggest outbreak of plague in recent times happened in Madagascar in 2017.
Normally the island nation sees between 200 to 700 cases annually. The recent outbreak recorded 2,119 confirmed, probable and suspected cases of plague, including 171 deaths in four months, according to WHO. The outbreak was contained after the organization responded with $1.5 million in emergency assistance, and 1.2 million doses of antibiotics. These were used for treating those infected with the disease, and the more than 7,000 people who had contact with them.
This year between January and March, 37 suspected cases have been reported in Madagascar with at least 21 confirmed to be the bubonic form of the plague. During this period, approximately 9 deaths were recorded.
The DR Congo has recorded an average of around 100 cases of plague annually since 2013, with a surge in incidences, across a greater geography, since 2019. Last year as the country battled the Covid-19 pandemic, the total number of cases was over 450.
This week UNICEF raised concerns that the disease is making a comeback through a combination of poverty and continuing insecurity, particularly in the eastern province of Ituri, which accounts for almost all the cases and deaths in the country. Between 2020 and 2021, there were 578 cases and 44 plague-related deaths in the province, according to UNICEF.
As of June this year, there have been a total of 117 suspected cases and 13 deaths reported in the DR Congo with 10 deaths suspected to be due to pneumonic plague, according to WHO. This form of the disease is particularly concerning as it is the only version that can be transmitted from person to person.
“‘The coronavirus pandemic has shown the importance of vaccines to defend populations from the threat caused by bacteria and viruses,” Andrew Pollard, director of the Oxford Vaccine Group, said in a statement. “Plague threatened the world in several horrific waves over past millennia, and, even today, outbreaks continue to disrupt communities. A new vaccine to prevent plague is important for them and for our health security.”
Sign up to the Quartz Africa Weekly Brief here for news and analysis on African business, tech, and innovation in your inbox.
Sign up for the Quartz Daily Brief, our free daily newsletter with the world’s most important and interesting news.
More stories from Quartz:
China’s boycott of Australia has redirected global flows of coal
A large new study shows the devastating effects of long Covid
The state assembly approved a bill that would allow duplexes on land previously reserved for single-family homes.
The lab that tested samples for Cassava's Alzheimer's study distanced itself from the biotech on Friday, and SAVA stock plunged — again.
(Bloomberg) — China hit back against allegations by the Biden administration that it was hindering the investigation into the start of the pandemic, after the U.S. intelligence community released a report saying the origin is still uncertain because of a lack of cooperation from Beijing. India administered a record 10.3 million doses of vaccine in a day in its battle to contain the virus. Florida, Scotland, Malaysia, Russia and New South Wales in Australia were among places around the world rep
The stock's been a wild ride for investors all year, and it's dropped more than 50% in two days. What's going on, and why am I bullish?
Delta Air Lines announced this week it would introduce a $200 health-insurance surcharge for workers not vaccinated against COVID-19.
Over the last few years, three tiny biotechs emerged out of nowhere to give amazing returns to early investors. Which biotech might pull off a similar feat in 2022?
Quanterix Corp. said that while it was previously engaged by Cassava Sciences Inc. to perform sample testing, the digitized biomarker analysis company said it, or its employees, "did not interpret the test results or prepare the data charts" presented by Cassava to the Alzheimer's Association International Conference (AAIC) in July, or otherwise. Earlier this week, in Cassava's response to a request the Food and Drug Administration halt clinical studies of Cassava's Alzheimer's treatment because
Someone told me, a health journalist, that doctors might secretly oppose COVID vaccinations. So I went straight to the source.View Entire Post ›
The COVID-19 vaccines available in the U.S. are highly effective because they trigger an immune response to produce antibodies that can protect against the virus. Of course, each vaccine is made differently, meaning that each can have a different effect on the body, work differently against new variants, and offer different levels of protection over time. But a new study has found that one current vaccine in particular may produce considerably more antibodies than the others.RELATED: If You Got
Feds tell judge that the combined companies will unfairly monopolize the market for blood screening that can detect multiple cancers.
Investing in biotech companies is hard. Shareholders are often subject to wild price swings based on results that may not translate to future studies. ALX Oncology (NASDAQ: ALXO), Vertex Pharmaceuticals (NASDAQ: VRTX), and Beam Therapeutics (NASDAQ: BEAM) are at different stages of the company lifecycle.
The risk of developing blood clots is much higher following a Covid-19 infection than after a first dose of either the Pfizer or AstraZeneca vaccine, an Oxford University study has found.
The surge in new COVID cases is putting an enormous strain on hospitals, jeopardizing patients who cannot get the medical attention they need because of a lack of space.
A U.S. appeals court on Thursday threw out a $1.2 billion ruling against Gilead Sciences Inc, finding a patent on a cancer therapy it was accused of infringing was invalid, in a blow to rival Bristol Myers Squibb Co. The two companies have been embroiled in a case involving accusations that Yescarta, the CAR-T cell cancer immunotherapy from Gilead's Kite Pharma unit, infringed on a patent for a similar therapy from Bristol's Juno Therapeutics. Last year, a federal judge increased the damages from a jury trial and ordered Gilead to pay Bristol Myers $1.2 billion in the patent infringement case.
The varying impacts of COVID-19 among ethnic groups might be partially due to genetic differences in the cell-surface protein the virus uses as a gateway, an international research team found. In the gene for ACE2 – the "receptor" protein through which the virus breaks into cells – they found rare variants that would alter the part of the protein to which the virus attaches itself. People who were not infected with the coronavirus were more likely to have a variant that decreases ACE2 levels, according to a report posted on Wednesday on medRxiv https://bit.ly/2Wy6FIw ahead of peer review.
Lisa Steadman spent more than a week inside Winter Haven Hospital battling COVID-19.
Anyone who has ever had their pain doubted by a doctor will understand the relief.View Entire Post ›
Shares of BeyondSpring (BYSI) stock exploded ~19% higher in Thursday trading after the NYC-based cancer researcher announced that it has inked an "exclusive commercialization and co-development agreement" with local partner Jiangsu Hengrui Pharmaceuticals to manufacture and sell BeyondSpring's plinabulin drug throughout Greater China (China, Hong Kong, Macau, and Taiwan). Plinabulin is described as a "first-in-class, selective immunomodulating microtubule-binding agent" which will be used to pre
In two Lexington cases, bystanders called for emergency aid when they saw strangers passed out in vehicles.
The Delta variant has changed the pandemic exponentially. The more contagious strain has not only shifted the trajectory of the virus, but also altered some of the more common symptoms. While we became familiar with the most frequently reported signs of COVID early in the pandemic—cough, fever, body aches, among others—we are now adjusting to a newer iteration of the virus that may present differently.RELATED: If You Have These Symptoms, Get Tested for COVID—Even If You're Vaccinated.Several doc

source

3 thoughts on “Scientists want to eradicate “Black Death” in Africa using Covid-19 vaccine technology – Yahoo Finance”

Leave a Comment

Your email address will not be published.